 of
evidence

Best Practice Statement

25. In a person with type 2 diabetes and peripheral artery disease:
with an eGFR > 30 mL/min/1.73m2, a sodium glucose cotransporter-2
(SGLT-2) inhibitor or a glucagon like peptide 1 receptor agonist with
demonstrated cardiovascular disease beneÔ¨Åt should be considered,
irrespective of the blood glucose level.
SGLT-2